TheraRadar
← Back
Data updated: Jun 28, 2026

SSM Cardinal Glennon Children's Medical Center

Biotech
Pharmaceuticals

SSM Cardinal Glennon Children's Medical Center is a biotechnology company with 1 FDA-approved products.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

SSM Cardinal Glennon Children's Medical Center's Key Drugs

SSM Cardinal Glennon Children's Medical Center's core commercial portfolio centers on Allocord — its most strategically important drugs approved in the last 15 years.

SSM Cardinal Glennon Children's Medical Center's Recent FDA Approvals

New NDA/BLA approvals for SSM Cardinal Glennon Children's Medical Center over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SSM Cardinal Glennon Children's Medical Center's Therapeutic Areas

Disease areas where SSM Cardinal Glennon Children's Medical Center has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

SSM Cardinal Glennon Children's Medical Center Pipeline Snapshot

Active clinical trials for SSM Cardinal Glennon Children's Medical Center across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Allocord leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling